Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc due to alleged violations of federal securities laws related to misleading statements about clinical trial results [4][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Mereo BioPharma to contact them to discuss their legal options [1]. - There is a deadline of April 6, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Mereo [2]. Group 2: Clinical Trial Results - Mereo BioPharma announced that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [5]. - Despite the failure to meet primary endpoints, the trials showed statistically significant improvements in bone mineral density on secondary endpoints, and no new safety concerns were identified [5]. Group 3: Market Reaction - Following the announcement of the failed trials, Mereo's stock price plummeted by $2.02 per share, or 87.64%, closing at $0.28 per share on December 29, 2025 [6].

Group 1 - Consumer Portfolio Services, Inc. (CPS) will hold a conference call on March 11, 2026, at 1:00 p.m. ET to discuss its fourth quarter 2025 operating results [1] - Participants can pre-register for the conference call through a provided link and will receive an email with dial-in options [2] - A replay of the conference call will be available for 12 months on the company's website starting two hours after the call concludes [2] Group 2 - Consumer Portfolio Services, Inc. is an independent specialty finance company that provides indirect automobile financing to individuals with past credit problems or limited credit histories [3] - The company purchases retail installment sales contracts primarily from franchised automobile dealerships, secured by late model used vehicles and, to a lesser extent, new vehicles [3] - CPS funds these contract purchases primarily through the securitization markets and services the contracts over their lives [3]

Core Viewpoint - The State Street SPDR U.S. Large Cap Low Volatility Index ETF (LGLV) is highlighted as a suitable investment option during periods of market volatility, providing lower risk exposure to large-cap stocks while maintaining equity market participation [1][2]. Group 1: Fund Overview - LGLV is designed to offer exposure to the least volatile stocks among the largest U.S. companies, making it a simple and low-cost option for investors seeking to mitigate risk [1]. - The fund has a historical annualized return of 12.4% over the last ten years, appealing to defensively minded investors [2]. Group 2: Market Context - Recent geopolitical tensions, particularly in the Middle East, have contributed to market sell-offs, prompting investors to consider lower volatility strategies [1]. - The fund has performed well in turbulent market conditions, showing a notable increase of approximately 7% year-to-date, contrasting with the flat performance of broader market indices [1][2]. Group 3: Performance Analysis - LGLV has demonstrated resilience during market downturns, performing better than many peers in years of market stress, such as 2018 and 2022 [2]. - The fund's performance metrics indicate it may lag during strong bull markets but excels in providing defensive equity exposure during volatile periods [2].

Core Insights - SAB Biotherapeutics, Inc. has advanced its lead candidate SAB-142 into the registrational Phase 2b SAFEGUARD study, with multiple patients already dosed and enrollment expected to complete by the end of 2026, with topline data anticipated in the second half of 2027 [1][3][7] - The company raised $175 million in an oversubscribed private placement to fully fund the SAFEGUARD study, indicating strong investor confidence [1][11] - SAB-142 has shown a favorable safety profile in Phase 1 clinical data, with no serum sickness and low immunogenicity observed across all cohorts [1][7][11] Financial Highlights - For the fiscal year 2025, SAB reported a net income of $13.3 million, a significant improvement from a net loss of $34.1 million in 2024 [13] - The company had cash, cash equivalents, and available-for-sale securities totaling $143.5 million as of December 31, 2025, providing operational runway through 2028 [13] - Research and development expenses for 2025 were $34.4 million, compared to $30.3 million in 2024, reflecting ongoing investment in clinical development [13] Clinical Development - SAB-142 is being developed as a disease-modifying immunotherapy for type 1 diabetes (T1D), with the potential to delay disease progression [1][11][14] - The Phase 1 study results confirmed that SAB-142 does not cause serum sickness and has low/no immunogenicity, supporting its chronic dosing in outpatient settings [7][11] - The company has activated multiple clinical trial sites in the U.S., Australia, and New Zealand for the SAFEGUARD study [7] Leadership and Governance - David Zaccardelli, Pharm.D., was appointed as Chair of the Board of Directors in January 2026, bringing over 20 years of biopharmaceutical experience [6] - Rita Jain, M.D., was also appointed as an Independent Director in January 2026, adding expertise in biopharmaceutical development and regulatory affairs [11]

Global Market Performance - Four out of nine global indexes tracked posted year-to-date gains as of March 9, 2026, with Japan's Nikkei 225 leading at a gain of 4.8% [1] - Canada's TSX follows closely with a gain of 4.7%, while China's Shanghai index shows a gain of 3.2% [1] - Conversely, India's BSE SENSEX has the largest year-to-date loss at -9.0%, followed by Germany's DAXK at -4.7% and France's CAC 40 at -2.9% [1] Historical Context - The performance of world markets is illustrated since the last recession starting from February 3, 2020, with comparative data from March 9, 2009 [1] - The S&P 500, TSX, CAC 40, and BSE SENSEX reached their lows on March 9, while the Nikkei 225 hit its low on March 10 [1] - A visualization of relative performance is provided, indexed to 800 on the March 9 start date, showing percent changes from that date to the latest weekly close [1] ETF Examples - Notable single country ETFs include SPDR S&P 500 ETF Trust (SPY), iShares MSCI Canada ETF (EWC), iShares MSCI Hong Kong ETF (EWH), iShares MSCI India ETF (INDA), KraneShares CSI China Internet ETF (KWEB), WisdomTree Europe Hedged Equity Fund (HEDJ), and WisdomTree Japan Hedged Equity Fund (DXJ) [1]

Core Insights - Global conflict has surged in 2026, impacting markets and creating volatility, particularly benefiting defense stocks, especially in drone technology [1] - Investors are encouraged to consider defense stocks as a viable investment category due to the rising demand driven by conflict [1] Defense Stocks and ETFs - Defense stocks, particularly drone companies, are experiencing increased demand due to their relevance in modern warfare and potential for new technology applications [1] - The Rex Drone ETF (DRNZ) offers targeted exposure to the drone industry, charging a fee of 65 basis points and focusing on firms that derive at least 50% of their revenues from drone or UAV development [1] - DRNZ has achieved a return of 29.4% over the last three months, driven by key players in the drone sector, such as DroneShield Limited (DRO) [1] - The Global X Defense Tech ETF (SHLD) charges a fee of 50 basis points and has returned 23.38% over the last three months, focusing on firms in big data, augmented reality, robotics, cybersecurity, and fuel systems [1] - The Invesco Aerospace & Defense ETF (PPA) charges 58 basis points and has returned 19.95% over the last three months, targeting major industry leaders like Lockheed Martin Corp. (LMT) [1] - PPA and SHLD provide exposure to drones through established industry leaders rather than pure-play companies [1]

Core Viewpoint - Precision Drilling Corporation has filed its annual disclosure documents with securities commissions in Canada and the SEC, highlighting its financial performance for the year ended December 31, 2025 [1][2]. Group 1: Financial Disclosure - Precision's 2025 Annual Report includes audited consolidated financial statements and management's discussion and analysis for the year ended December 31, 2025, with results previously released on February 11, 2026 [2]. - The Annual Report and Annual Information Form have been filed on SEDAR+ and EDGAR systems, and are accessible on Precision's website [3]. Group 2: Shareholder Meeting - Precision's 2026 Annual Meeting of Shareholders is scheduled to be held in a virtual-only format on May 14, 2026, at 10:00 a.m. MDT [4]. Group 3: Company Overview - Precision is a leading provider of safe and environmentally responsible services to the energy industry, featuring an extensive fleet of Super Series drilling rigs and a digital technology portfolio known as Alpha™ [5]. - The company emphasizes its commitment to reducing environmental impact through its EverGreen™ suite of environmental solutions, alongside offering well service rigs, rental equipment, and technical support services [5]. - Precision is headquartered in Calgary, Alberta, Canada, and is publicly traded on the Toronto Stock Exchange under the symbol "PD" and on the New York Stock Exchange under "PDS" [6].

Core Insights - Alaris Equity Partners Income Trust achieved record performance in 2025, closing the year with 23 private company partners and deploying $385 million of capital, marking all-time highs [3] - The book value per share reached an all-time high of $25.10, with a distribution increase of 9% reflecting strong capital deployment and partner growth [3][4] - The Trust's Payout Ratio remained below the targeted range of 65%-70%, indicating a commitment to sustainable dividends and capital allocation priorities [3][4] Financial Performance - Total revenue and operating income increased by 15.9% in Q4 and 14.0% for the year, driven by a $73.2 million net unrealized gain on partner investments [4][9] - Net book value per unit increased by $0.64 to $24.79 in 2025, despite a $1.13 per unit unrealized foreign exchange loss [4][8] - Alaris Net Distributable Cash Flow decreased by 24.6% in Q4 and 16.1% for the year, reflecting timing and variability in common distributions [4][14] Partner Distributions and Portfolio Performance - Total Partner distribution revenue decreased by 2.6% in Q4 and 2.5% for the year, with contributions from new investments partially offsetting lower common distributions [11] - The weighted average Earnings Coverage Ratio for Alaris' Portfolio Partners was maintained at 1.5x, with 15 of 23 partners above this threshold [4][11] - Alaris estimates an average positive reset of approximately 4.0% on annual preferred distributions resetting in 2026, resulting in an estimated $4.8 million of incremental Run Rate Revenue [4][15] Capital Deployment and Outlook - Alaris invested a record $387.4 million during 2025, including significant investments in Optimus and Renew [4][9] - The Trust's total Partner revenue for Q1 2026 is expected to be approximately $46.9 million, reflecting seasonal distribution timing and recent investment activity [15] - Run Rate Revenue for the next twelve months is estimated at approximately $200.1 million, with a Run Rate Payout Ratio expected to range between 60% and 65% [15][16]

Core Viewpoint - Canacol Energy Ltd. has secured debtor-in-possession (DIP) financing to support its ongoing operations amid insolvency proceedings, with the financing approved by Canadian and U.S. courts [1][2]. Group 1: DIP Financing Details - The company entered into a commitment letter for DIP financing with an ad hoc group of holders of its 5.75% senior unsecured notes due 2028 [1]. - The DIP financing was approved by the Alberta Court of King's Bench on December 11, 2025, and recognized by the U.S. Bankruptcy Court on December 18, 2025 [1]. - The company has closed the first subsequent advance under the DIP Commitment Letter after meeting all conditions precedent [2]. Group 2: Ongoing Monitoring and Reporting - Canacol has provided material non-public information (MNPI) to the DIP lenders, which is available for review on the website of the court-appointed Monitor, KPMG Inc. [3]. - Investors are encouraged to monitor the Monitor's website for updates regarding the company's business, operations, and insolvency proceedings [3]. Group 3: Company Overview - Canacol Energy Ltd. is primarily engaged in natural gas exploration and production, with operational activities located in Colombia [4].

Market Overview - The market experienced volatility influenced by oil prices, with the S&P 500's VIX decreasing by almost four points, indicating reduced fear in the market [8] - Oil prices peaked near 120 but closed lower around 100, providing the market a chance to stabilize [8] Technology Sector - Technology stocks, particularly in the memory segment, showed strong performance, with SanDisk rising 11% following price target increases from analysts [2] - Micron's DRAM prices are expected to rise by 171% year-over-year, while NAND prices are projected to increase by 127% [3] South Korean Chip Industry - Concerns have emerged regarding the South Korean chip industry due to potential impacts from rising energy prices linked to the conflict in Iran [4] - South Korean memory stocks faced heavy selling pressure, contrasting with the performance of US memory stocks [3] Chinese Market Insights - Chinese stocks have shown resilience, experiencing less selling pressure compared to regional counterparts, attributed to China's insulation from energy shocks and stockpiling strategies [5] - Chinese consumer prices reached a three-year high, which is viewed positively in light of previous deflationary pressures [5] Upcoming Earnings and Economic Data - Upcoming earnings reports from Oracle, Kohl's, and NEO are anticipated, with particular attention on Oracle's performance amid discussions on AI and credit risk [14][15] - The housing sector is being monitored for updates, especially with mortgage rates declining [10] - Chinese trade data is expected to be released, which is crucial for global investors given China's significant trade surplus [11]